The technology, as well as the clinical application, has been described in over 300 publications in high ranking journals, including, but not limited to: Nature Medicine, Blood, JASN, Lancet Oncology, and Mass Spectrometry Reviews. These high ranking scientific publications have established mosaiques as the leading player in the field of clinical proteome analysis, and have also resulted in the definition of standard practices within the clinical proteomics field and the construction of an unique academic framework of worldwide collaborations with over 60 universities (e.g. Harvard, UVA, NIH, FDA, INSERM, Univ. Glasgow, Steno Diabetes Center, etc.) and industrial institutions. Mosaiques also performs clinical trials in cooperation with the pharmaceutical industry, enabling improvement of therapy and therapeutics, based on an individual’s molecular polypeptide signature.